Choose Language
Select a language for news translation.
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to the S&P 500 healthcare sector at a low cost, whereas the Invesco Bio…
Healthcare ETFs FHLC and IYH both offer sector exposure but differ in cost and diversification. FHLC’s lower fee and broader 334-stock holdings make it the mor…
Written by Eric Volkman for The Motley Fool -> It had a good second quarter, fueled by sales growth in top blockbuster drugs. It also topped analyst estimate…
Written by Andy Gould for The Motley Fool -> The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. P…
Written by Prosper Junior Bakiny for The Motley Fool -> Revolution Medicines has a promising cancer drug in development. Even with this medicine's prospects,…
Written by Thomas Niel for The Motley Fool -> After reporting an earnings beat last quarter, AbbVie could once again beat expectations in the second quarter, …
Written by Jake Lerch for The Motley Fool -> State Street Health Care Select Sector SPDR ETF maintains a significantly lower expense ratio of 0.08% compared t…
Written by Jake Lerch for The Motley Fool -> State Street Health Care Select Sector SPDR ETF has a much lower expense ratio and significantly higher assets un…
Vanguard’s VHT offers lower fees and double the dividend yield of Invesco’s IBBQ through broader healthcare exposure. This makes VHT a cost-effective choice fo…
The State Street Health Care Select Sector SPDR ETF is preferred over the VanEck Pharmaceutical ETF due to its lower expense ratio and broader diversification …
The VanEck Pharmaceutical ETF (PPH) targets 25 pharmaceutical companies, while the State Street Health Care Select Sector SPDR ETF (XLV) includes 60 positions …
